A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.

被引：1
|
作者：
Hellmann, Matthew David
Shimizu, Toshio
Doi, Toshihiko
Hodi, F. Stephen
Rottey, Sylvie
Aftimos, Philippe Georges
Liu, Zhuqing Tina
de Mendizabal, Nieves Velez
Szpurka, Anna M.
Piao, Yongzhe
Vangerow, Burkhard
Gandhi, Leena
Leow, Ching Ching
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] NCCH, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[7] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[10] Eli Lilly & Co, Bad Homburg, Germany
[11] NYU Perlmutter Canc Ctr, New York, NY USA
[12] Eli Lilly & Co, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS2654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2654
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
    Yap, Timothy A.
    LoRusso, Patricia M.
    Wong, Deborah J.
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Holz, Josefin-Beate
    Grabowska, Urszula
    Gradinaru, Cristian
    Leung, Kin-Mei
    Marshall, Sylwia
    Reader, Claire S.
    Russell, Roslin
    Sainson, Richard C. A.
    Seal, Claire J.
    Shepherd, Christopher J.
    Germaschewski, Fiona
    Gliddon, Daniel
    Stern, Omer
    Young, Lesley
    Brewis, Neil
    Kayitalire, Louis
    Morrow, Michelle
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 888 - 898
  • [22] A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
    Yap, Timothy A.
    Papadopoulos, Kyriakos P.
    LoRusso, Patricia
    Wong, Deborah J. L.
    Hu-Lieskovan, Siwen
    Holz, Josefin-Beate
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC.
    Liu, Jiajian
    Luan, Y.
    Deng, H.
    Wang, F.
    Wang, C.
    Zhang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
    Voskoboynik, Mark
    Richardson, Gary Edward
    Mileshkin, Linda R.
    McNeil, Catriona M.
    Horvath, Lisa
    Benedetti, Fabio M.
    Choy, Gavin S.
    Sankar, Neil
    McCurry, Shelly
    Zhang, Xiaoling
    Gao, Min
    Shah, Ajit K.
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Plasma PD-L1 concentration in patients with brain metastases from solid tumors.
    Berghoff, Anna Sophie
    Pajenda, Sahra
    Ilhan-Mutlu, Ayseguel
    Widhalm, Georg
    Dieckmann, Karin
    Hainfellner, Johannes A.
    Wagner, Ludwig
    Zielinski, Christoph
    Birner, Peter
    Bartsch, Rupert
    Preusser, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.
    Coward, Jermaine
    Lemech, Charlotte Rose
    Mislang, Anna Rachelle Austria
    Parakh, Sagun
    Underhill, Craig
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
    Hollebecque, Antoine
    Chung, Hyun C.
    de Miguel, Maria J.
    Italiano, Antoine
    Machiels, Jean-Pascal
    Lin, Chia-Chi
    Dhani, Neesha C.
    Peeters, Marc
    Moreno, Victor
    Su, Wu-Chou
    Chow, Kay Hoong
    Galvao, Violeta R.
    Carlsen, Michelle
    Yu, Danni
    Szpurka, Anna M.
    Zhao, Yumin
    Schmidt, Shelly L.
    Gandhi, Leena
    Xu, Xiaojian
    Bang, Yung-Jue
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6393 - 6404
  • [28] GENERATION OF AZD7789, A NOVEL PD-1 AND TIM-3 TARGETING BISPECIFIC ANTIBODY, WHICH BINDS TO A DIFFERENTIATED EPITOPE OF TIM-3
    Clancy-Thompson, Eleanor
    Perry, Trinity
    Pryts, Stacy
    Jaiswal, Ashvin
    Oganesyan, Vaheh
    van Dyk, Nydia
    Yang, Chunning
    Garcia, Andrew
    Yu, Wenhan
    Moynihan, James
    Miller, Caroline
    Mulgrew, Kathy
    Cobbold, Mark
    Mazor, Yariv
    Hammond, Scott
    Pollizzi, Kristen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A481 - A481
  • [29] PHASE I SAFETY AND PRELIMINARY EFFICACY OF PM8002 IN SUBJECTS WITH ADVANCED SOLID TUMORS, A BISPECIFIC ANTIBODY TARGETING PD-L1 AND VEGF-A
    Guo, Ye
    Luo, Suxia
    Qin, Yanru
    Yin, Yongmei
    Li, Guiling
    Wang, Jingfen
    Li, Yongsheng
    Guo, Jun
    Zhang, Feng
    Huang, Yi
    Luo, Hong
    Lv, Dongqing
    Ying, Cheng
    Wang, Chunyan
    Chou, Chuan-Chu
    Gong, Chundan
    Chang, Ruixia
    Liu, Jing
    Hu, Guoqiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A758 - A758
  • [30] NB202: A bispecific anti-PD1/TIM-3 antibody for cancer immunotherapy
    Dong, Jinyu
    Zhang, Yu
    Wang, Binbin
    Wang, Dong
    Bu, Tingting
    Ni, Jie
    Nayak, Bishnu
    Dong, Xin
    CANCER RESEARCH, 2024, 84 (06)
12345